Accessibility Menu
Surrozen logo

Surrozen(NASDAQ) SRZN

Market Cap$297.46MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-83%
5 Year-82%
1 Year+184%
1 Month+12%
$25.34
+17.10%
+3.70Today
After hours$25.49+$0.15 (+0.59%)
Surrozen last closing stock price
MetricPriceDate
Last closeUSD 25.622026-08-07
Surrozen stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+15.35%USD 22.212026-07-31
1 month+11.98%USD 22.882026-07-08
3 month-11.53%USD 28.962026-05-08
Year to date+13.36%USD 22.602025-12-31
1 year+183.72%USD 9.032025-08-07
3 year+103.07%USD 12.622023-08-08
5 year-82.3%USD 144.752021-08-06
Since inception-83.11%USD 151.652021-01-11

Surrozen Financials at a Glance

Market Cap

$297.46MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$11.51M

Net Income (TTM)

-$332.13M

EPS (TTM)

-$44.28

P/E Ratio

-0.62

Dividend

$0.00

Beta (Volatility)

0.71 (Low)

Price

$25.34

Volume

371,199

Open

$24.84

Previous Close

$25.62

Daily Range

$22.30 - $27.32

52-Week Range

$9.55 - $35.00

Estimated Earnings Date

Aug 6, 2026

SRZN News

Foolcom-Featured.png

Surrozen Reports Q2 Profit on Gains

Motley Fool Markets TeamAug 8, 2025

SRZN: Motley Fool Moneyball Superscore

56

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Surrozen

Surrozen makes medicines to help the body fix damaged tissues. It creates eye treatments for people suffering from vision loss. These drugs aim to repair tissue and improve patient sight.

Fixing the Body From Within

  • SZN-413: Partnered bi-specific antibody targeting retinal vascular integrity through specific biological pathways; accounted for 100% of revenue in Q1 2026.
  • SZN-8141: Experimental therapy for retinal diseases that combines vessel growth control and tissue repair signaling.
  • SZN-8143: Multi-action antibody candidate designed to reduce eye inflammation and restore tissue function.
  • Research Programs: Laboratory-stage efforts focused on healing corneal injuries and protecting eye nerves.

Strategic Deals and Lab Milestones

  • Partnered with Boehringer Ingelheim International GmbH in October 2022 to develop and commercialize antibody-based eye treatments.
  • Established a $175 million private financing agreement in March 2025 to support clinical operations through a two-stage investment structure.
  • Raised $26.9 million in the first quarter of 2026 through an at-the-market equity sales program with TD Cowen.
  • Achieved a $5 million research milestone in March 2026 following successful toxicology studies for its lead partnered antibody program.

What Makes Surrozen Different

Surrozen uses proprietary engineering platforms to create antibodies that selectively activate natural tissue-repair pathways within the body. This approach allows the company to target specific organs like the eye while minimizing biological activity in other areas to reduce potential side effects.

A Look at the Books

  • Revenue reached $5 million in Q1 2026, up 408.6% from $983,000 in Q1 2025.
  • Net loss deepened to $127.5 million in Q1 2026, compared to a $27 million loss in Q1 2025.
  • Operating loss worsened to $10.5 million in Q1 2026, representing a 9.5% increase year-over-year.
  • Cash and cash equivalents totaled $106.9 million as of March 31, 2026.

The Final Word

Surrozen has transitioned from broad biological research to a concentrated focus on repairing vision through tissue-selective antibody engineering. Its long-term trajectory depends on advancing its current pipeline into clinical testing while managing high non-cash expenses related to its financing structures.

AI Generated • May 8, 2026

Industry

Biotechnology

Sector

Health Care

Employees

44

CEO

Craig C. Parker, MBA

Website

www.surrozen.com

Headquarters

South San Francisco, CA 94080, US

SRZN Financials

Key Financial Metrics (TTM)

Gross Margin

99.44%

Operating Margin

-385.28%

Net Income Margin

-2885.33%

Return on Equity

187.62%

Return on Capital

N/A

Return on Assets

-287.29%

Earnings Yield

-1.61%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$297.46MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

11.61M

Volume

371.20K

Avg. Volume

177.53K

Financials (TTM)

Gross Profit

$11.45M

Operating Income

-$44.35M

EBITDA

-$331.84M

Operating Cash Flow

-$47.26M

Capital Expenditure

-$342.00K

Free Cash Flow

-$47.60M

Cash & ST Invst.

$102.04M

Total Debt

$6.32M

Surrozen Performance Analysis

Surrozen annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 12,500,000N/A
20232023-12-31USD 0N/A
20242024-12-31USD 10,655,000N/A
20252025-12-31USD 3,477,000-67.4%
Surrozen sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31-46.3%
Q12026-03-31847.0%
Q22026-06-30N/A
Surrozen annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -15.55-33.5%
20232023-12-31USD -21.3337.1%
20242024-12-31USD -21.671.6%
20252025-12-31USD -32.3749.3%
Surrozen sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-427.8%
Q42025-12-31-185.5%
Q12026-03-3151.2%
Q22026-06-3096.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$5.00M

+408.6%

Gross Profit

$5.00M

+408.6%

Gross Margin

100.00%

N/A

Market Cap

$297.46MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$6.76M

N/A

Employees

44

N/A

Net Income

$50.18M

+26.2%

EBITDA

$50.29M

+26.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$102.04M

+12.9%

Total Debt

$6.32M

-15.9%

Accounts Receivable

$5.00M

+94.6%

Inventory

$0.00

N/A

Long Term Debt

$4.33M

-31.5%

Short Term Debt

$1.99M

+65.9%

Return on Assets

-2.87%

N/A

Return on Invested Capital

-41.61%

N/A

Free Cash Flow

-$20.05M

-227.0%

Operating Cash Flow

-$19.91M

-225.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IRDOpus Genetics, Inc.
$3.66-1.61%
AGENAgenus Inc.
$6.96-7.08%
GLSIGreenwich LifeSciences, Inc.
$14.36+0.84%
SEERSeer, Inc.
$2.17-0.91%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$133.11+0.16%
TTDThe Trade Desk
$13.80-0.22%
NVDANvidia
$223.96+0.02%
TLTiShares Trust - iShares 20+ Year Treasury Bond ETF
$82.76+0.00%

Questions About SRZN

What is the current price of Surrozen?

Surrozen is trading at $25.62 per share.

What is the 52-week range for Surrozen?

Over the past 52 weeks, Surrozen has traded between $9.55 and $35.00.

How much debt does Surrozen have?

As of the most recent reporting period, Surrozen reported total debt of $6.32M.

How much cash does Surrozen have on hand?

Surrozen reported $102.04M in cash and cash equivalents in its most recent financial results.

What is Surrozen’s dividend yield?

Surrozen does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services